Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Osimertinib Plus Chemotherapy for EGFR-mutant Stage III N2 Non-squamous Non-small Cell Lung Cancer

NCT05011487 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05011487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05011487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Osimertinib Plus Chemotherapy for EGFR-mutant Stage III N2 Non-squamous Non-small Cell Lung Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
August 13, 2021
Completion date
September 30, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer